Phase 3 Aipac 003 Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nuhad K. Ibrahim, MD, discusses the investigation of eftilagimod alpha plus in hormone receptor–positive HER2-negative or HER2-low metastatic breast cancer in the phase 3 AIPAC-003 trial.

United statesNuhadk ibrahimDivision of cancer medicineDepartment of breast medical oncologyUniversity of texas md anderson cancer centerBreast medical oncologyCancer medicineCancer centerPatients with breast cancerHer2 negativeHer2 lowBreast cancerEftilagimod alphaPhase 3 aipac 003 trial